Shots:

• Amunix to receive $40M up front- up to $1.5B as development & commercial milestones along with royalties on sales of products. Roche to leverage Amunix’s XTEN technology platform to develop novel non-oncology therapies for undisclosed targets
• The agreement follows Amunix’s previous technology assessment with Roche which focused on utilizing XTEN to extend the half-life of the drugs
• Amunix’s XTEN technology platform consists of unstructured polypeptides and has been validated via collaboration with biopharmaceutical companies to extend the half-life of therapies with low associated immunogenicity  

Click here ­to­ read full press release/ article 

 Ref: GlobeNewswire  | Image: Roche